AR055610A1 - Composicion farmaceutica solida que comprende 1- (4-cloro-anilino) -4-(4- piridil - metil) ftalazina y un modificador del ph - Google Patents

Composicion farmaceutica solida que comprende 1- (4-cloro-anilino) -4-(4- piridil - metil) ftalazina y un modificador del ph

Info

Publication number
AR055610A1
AR055610A1 ARP060103618A ARP060103618A AR055610A1 AR 055610 A1 AR055610 A1 AR 055610A1 AR P060103618 A ARP060103618 A AR P060103618A AR P060103618 A ARP060103618 A AR P060103618A AR 055610 A1 AR055610 A1 AR 055610A1
Authority
AR
Argentina
Prior art keywords
anilino
modifier
methyl
ftalazine
piridil
Prior art date
Application number
ARP060103618A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR055610A1 publication Critical patent/AR055610A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que comprenden el compuesto de fármaco dependiente del pH de 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del pH.
ARP060103618A 2005-08-22 2006-08-18 Composicion farmaceutica solida que comprende 1- (4-cloro-anilino) -4-(4- piridil - metil) ftalazina y un modificador del ph AR055610A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0517205.1A GB0517205D0 (en) 2005-08-22 2005-08-22 Organic compounds

Publications (1)

Publication Number Publication Date
AR055610A1 true AR055610A1 (es) 2007-08-29

Family

ID=35098110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103618A AR055610A1 (es) 2005-08-22 2006-08-18 Composicion farmaceutica solida que comprende 1- (4-cloro-anilino) -4-(4- piridil - metil) ftalazina y un modificador del ph

Country Status (24)

Country Link
US (1) US20100280035A1 (es)
EP (1) EP1919459A1 (es)
JP (1) JP2009504795A (es)
KR (1) KR20080037680A (es)
CN (1) CN101287452A (es)
AR (1) AR055610A1 (es)
AU (1) AU2006284133A1 (es)
BR (1) BRPI0615014A2 (es)
CA (1) CA2619396A1 (es)
CR (1) CR9713A (es)
CU (1) CU20080025A7 (es)
EC (1) ECSP088202A (es)
GB (1) GB0517205D0 (es)
GT (1) GT200600379A (es)
IL (1) IL188921A0 (es)
MX (1) MX2008002493A (es)
NO (1) NO20081440L (es)
PA (1) PA8691901A1 (es)
PE (1) PE20070421A1 (es)
RU (1) RU2008110740A (es)
TW (1) TW200738284A (es)
UY (1) UY29757A1 (es)
WO (1) WO2007022944A1 (es)
ZA (1) ZA200800394B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958616A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
US20120308662A1 (en) * 2011-06-01 2012-12-06 Nitto Denko Corporation Particulate preparation and method for producing the same
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
AU2017290354C1 (en) * 2016-06-29 2023-07-06 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN113559074B (zh) * 2020-06-28 2023-04-21 海创药业股份有限公司 一种喹啉类化合物缓释片及其制备方法
EP4176902A1 (en) * 2020-07-02 2023-05-10 Artham Therapeutics Inc. Oral pharmaceutical composition and method for producing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet

Also Published As

Publication number Publication date
WO2007022944A1 (en) 2007-03-01
JP2009504795A (ja) 2009-02-05
GB0517205D0 (en) 2005-09-28
PA8691901A1 (es) 2009-05-15
EP1919459A1 (en) 2008-05-14
IL188921A0 (en) 2008-08-07
KR20080037680A (ko) 2008-04-30
UY29757A1 (es) 2007-03-30
CN101287452A (zh) 2008-10-15
RU2008110740A (ru) 2009-09-27
NO20081440L (no) 2008-03-19
AU2006284133A1 (en) 2007-03-01
BRPI0615014A2 (pt) 2011-05-03
TW200738284A (en) 2007-10-16
MX2008002493A (es) 2008-04-03
ZA200800394B (en) 2009-08-26
GT200600379A (es) 2007-03-28
PE20070421A1 (es) 2007-04-25
CR9713A (es) 2008-04-16
ECSP088202A (es) 2008-03-26
CU20080025A7 (es) 2010-03-25
US20100280035A1 (en) 2010-11-04
CA2619396A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AR055610A1 (es) Composicion farmaceutica solida que comprende 1- (4-cloro-anilino) -4-(4- piridil - metil) ftalazina y un modificador del ph
ATE479687T1 (de) Kinaseinhibitoren
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MY164646A (en) Nicotine lozenge compositions
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
ATE528989T1 (de) Kristalline feste rasagilin-base
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CR10422A (es) Formulaciones de dosificacion solida
ATE429906T1 (de) Trockene aripiprazolformulierungen
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EA201170483A1 (ru) Твердая фармацевтическая композиция
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
DE602008004235D1 (de) Stabile wässrige g-csf-formulierungen
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
ATE461189T1 (de) Neue 6-pyridylphenanthridine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal